Aldeyra Therapeutics (ALDX) Reports Q3 Loss of $0.52

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.52), versus ($0.32) reported last year.

"The third quarter was highlighted by positive results from our Phase 2b clinical trial of reproxalap in dry eye disease and an investigator-sponsored Phase 1/2 clinical trial of ADX-1612 in malignant mesothelioma," commented Todd C. Brady, M.D., Ph.D. "In addition, we completed a successful financing to support a broad and diversified clinical development plan that includes Phase 3 clinical trials in dry eye disease, noninfectious anterior uveitis, allergic conjunctivitis, and Sjögren-Larsson Syndrome. We look forward to the announcement of our next major milestone, results from the ALLEVIATE Phase 3 clinical trial in allergic conjunctivitis, in early 2019."

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• C.H. Robinson acquires DeSpir Logistics for $75 million
• AeroVironment restates quarterly financials, citing $89M goodwill error